Cargando…
circGSAP: A New Clinical Biomarker for Idiopathic Pulmonary Hypertension?
Autores principales: | Sun, Xishi, Chen, Riken, Yao, Xiaoyun, Zheng, Zhenzhen, Wang, Chaoyu, Chen, Jiahui, Cheng, Junfen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Thoracic Society
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8787255/ https://www.ncbi.nlm.nih.gov/pubmed/34739355 http://dx.doi.org/10.1164/rccm.202108-1868LE |
Ejemplares similares
-
Treatment of Pulmonary Hypertension: Is Triple Therapy Necessarily Better than Monotherapy?
por: Sun, Xishi, et al.
Publicado: (2021) -
CircGSAP regulates the cell cycle of pulmonary microvascular endothelial cells via the miR-942-5p sponge in pulmonary hypertension
por: Sun, Yuanyuan, et al.
Publicado: (2022) -
CircGSAP alleviates pulmonary microvascular endothelial cells dysfunction in pulmonary hypertension via regulating miR-27a-3p/BMPR2 axis
por: Sun, Yuanyuan, et al.
Publicado: (2022) -
Learning curve and analysis of curative effects after balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
por: Hong, Cheng, et al.
Publicado: (2023) -
Pulmonary Hypertension: A Predictor of Lung Cancer Prognosis?
por: Zheng, Zhenzhen, et al.
Publicado: (2021)